Gedeon Richter PLC

BUSE:RICHTER Stock Report

Market Cap: Ft2.2t

Gedeon Richter Future Growth

Future criteria checks 0/6

Gedeon Richter is forecast to grow earnings and revenue by 0.7% and 3.8% per annum respectively. EPS is expected to grow by 2.4% per annum. Return on equity is forecast to be 16.2% in 3 years.

Key information

0.7%

Earnings growth rate

2.41%

EPS growth rate

Pharmaceuticals earnings growth11.8%
Revenue growth rate3.8%
Future return on equity16.22%
Analyst coverage

Good

Last updated11 Jun 2026

Recent future growth updates

Analysis Article • Nov 09

Gedeon Richter PLC Just Missed Revenue By 8.5%: Here's What Analysts Think Will Happen Next

Gedeon Richter PLC ( BUSE:RICHTER ) shareholders are probably feeling a little disappointed, since its shares fell 5.0...
Analysis Article • Aug 09

The Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Last week saw the newest half-yearly earnings release from Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt...

Recent updates

Narrative Update • Jun 26

RICHTER: Future Diabetes Franchise And Dividend Policy Will Shape Balanced Outlook

Analysts have adjusted their fair value estimate for Gedeon Richter from HUF 11,949 to HUF 12,931, reflecting updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E expectation. What's in the News Gedeon Richter and Hetero Labs signed a global collaboration agreement for the joint development, registration, and commercialization of Semaglutide Injection, a generic version of Ozempic.
New Narrative • Mar 22

Women’s Healthcare Reliance And CDMO Risks Will Pressure Future Margins And Earnings

Catalysts About Gedeon Richter Gedeon Richter is a Hungary based pharmaceutical company with business lines in women’s healthcare, central nervous system therapies, biosimilars, contract development and manufacturing, and general medicine. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 06

Women's Health And Biosimilars Will Drive Stronger Long Term Prospects

Catalysts About Gedeon Richter Gedeon Richter is a Hungary based pharmaceutical company focused on women's healthcare, central nervous system therapies and biosimilars, supported by a wider general medicines and CDMO business. What are the underlying business or industry changes driving this perspective?
Analysis Article • Feb 05

What You Can Learn From Gedeon Richter PLC's (BUSE:RICHTER) P/E

With a median price-to-earnings (or "P/E") ratio of close to 10x in Hungary, you could be forgiven for feeling...
Analysis Article • Nov 14

Gedeon Richter's (BUSE:RICHTER) Profits May Not Reveal Underlying Issues

The stock price didn't jump after Gedeon Richter PLC ( BUSE:RICHTER ) posted decent earnings last week. Our analysis...
Analysis Article • Nov 09

Gedeon Richter PLC Just Missed Revenue By 8.5%: Here's What Analysts Think Will Happen Next

Gedeon Richter PLC ( BUSE:RICHTER ) shareholders are probably feeling a little disappointed, since its shares fell 5.0...
Analysis Article • Nov 06

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Screens Well But There Might Be A Catch

When close to half the companies in Hungary have price-to-earnings ratios (or "P/E's") above 13x, you may consider...
Analysis Article • Aug 09

The Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Last week saw the newest half-yearly earnings release from Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt...

Earnings and Revenue Growth Forecasts

BUSE:RICHTER - Analysts future estimates and past financials data (HUF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,098,192313,070251,608340,3565
12/31/20271,023,546286,154231,273313,3026
12/31/2026951,724259,474212,575311,2886
3/31/2026925,140229,477225,210290,344N/A
12/31/2025928,962232,335209,999276,403N/A
9/30/2025901,323227,294242,785305,855N/A
6/30/2025903,361221,007213,794274,257N/A
3/31/2025878,137239,168222,901285,348N/A
12/31/2024857,545239,244215,651279,369N/A
9/30/2024839,601211,635150,344217,409N/A
6/30/2024811,415229,129124,175193,076N/A
3/31/2024798,937187,87464,812135,657N/A
12/31/2023805,158158,85029,031123,670N/A
9/30/2023825,94895,56351,264146,907N/A
6/30/2023855,211123,42658,001152,541N/A
3/31/2023844,351157,72058,585152,053N/A
12/31/2022802,755169,076114,417185,996N/A
9/30/2022755,061242,521108,858175,266N/A
6/30/2022694,772198,297103,601169,384N/A
3/31/2022657,758149,79293,437160,260N/A
12/31/2021630,595139,626-3,393139,904N/A
9/30/2021604,708114,689-22,023118,835N/A
6/30/2021584,88799,067-14,570120,049N/A
3/31/2021566,244102,570-8,138125,391N/A
12/31/2020566,776104,68366,882133,520N/A
9/30/2020555,12468,48268,707143,298N/A
6/30/2020544,96468,13044,478120,856N/A
3/31/2020527,60854,12346,506117,941N/A
12/31/2019507,79447,135N/A98,214N/A
9/30/2019490,66849,451N/A73,813N/A
6/30/2019462,57636,071N/A83,211N/A
3/31/2019453,15142,857N/A84,171N/A
12/31/2018445,48435,348N/A100,343N/A
9/30/2018434,07811,939N/A112,349N/A
6/30/2018441,99718,899N/A101,483N/A
3/31/2018445,6262,997N/A96,266N/A
12/31/2017444,3568,885N/A83,747N/A
9/30/2017439,82268,291N/A91,977N/A
6/30/2017429,20766,829N/A83,315N/A
3/31/2017413,02174,992N/A83,140N/A
12/31/2016389,69066,200N/A77,419N/A
9/30/2016372,68952,016N/A76,144N/A
6/30/2016368,53944,525N/A92,174N/A
3/31/2016366,88950,419N/A96,778N/A
12/31/2015365,22053,863N/A95,047N/A
9/30/2015366,63140,482N/A80,771N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RICHTER's forecast earnings growth (0.7% per year) is below the savings rate (6.8%).

Earnings vs Market: RICHTER's earnings (0.7% per year) are forecast to grow slower than the Hungarian market (12.2% per year).

High Growth Earnings: RICHTER's earnings are forecast to grow, but not significantly.

Revenue vs Market: RICHTER's revenue (3.8% per year) is forecast to grow slower than the Hungarian market (5.4% per year).

High Growth Revenue: RICHTER's revenue (3.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RICHTER's Return on Equity is forecast to be low in 3 years time (16.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/06 17:41
End of Day Share Price 2026/08/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gedeon Richter PLC is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon MatherBarclays
Patrick Andrew WoodBofA Global Research
Gabor BuktaConCorde Securities Ltd.